Summary: Apolipoprotein E is one of the apolipoproteins involved in cholesterol metabolism. Three major isoforms are present in men: E2, E3, E4 corresponding to the products of three alleles. They have different affinities for receptors and the ε4 allele is a risk factor for cardiovascular diseases and more recently for Alzheimer's disease. We describe here the production, by heterologous expression in Escherichia coli, of the three apolipoprotein Ε isoforms for use in both research and clinical laboratories. By Surface Plasmon Resonance, the purified recombinant apolipoprotein Ε isoforms were able to recognize three monoclonal anti-human apolipoprotein Ε antibodies with affinity constants close to those of purified human apolipoprotein E. For receptor binding studies, the recombinant apolipoprotein Ε isoforms were associated with VLDL isolated from apolipoprotein Ε knockout mice. Although the association of the recombinant apolipoproteins Ε with the mouse VLDL was less efficient than that of human plasma apolipoprotein E3, the recombinant apolipoprotein E3 and apolipoprotein E4 complexes competed efficiently with 125 I-labelled LDL for binding to the LDL receptor in J774 macrophages, whereas the recombinant apolipoprotein E2-VLDL complexes did not. These results suggest that the recombinant apolipoprotein Ε isoforms have biological properties similar to the human apolipoprotein Ε isoforms.
Introduction
Apolipoprotein Ε is a component of several classes of lipoproteins that serve as lipid transport particles in human plasma and body fluids (1) . Apolipoprotein Ε is synthesized with an 18 amino acid signal peptide that is cleaved cotranslationally (2) . The resulting 299 amino acid protein is a secretory glycoprotein expressed by a variety of tissues, essentially liver parenchymal cells, but also macrophages, adrenal glands and astrocytes in the brain where it has been shown to be the major apolipoprotein (3, 4) . The protein is secreted in a highly sialylated form but is then processed to its plasma state in which 80% of the protein is desialylated (3) .
Human apolipoprotein Ε is polymorphic. This polymorphism stems from three common alleles ε2, ε3 and ε4 (5) . Three homozygous phenotypes (apolipoprotein E2/E2, E3/E3 and E4/E4) and three heterozygous phenotypes (apolipoprotein E3/E2, E3/E4 and E4/E2) arise from the expression of any two of the alleles. In the Caucasian population the prevalence is: apolipoprotein E2/E2 1%, apolipoprotein E3/E3 60%, apolipoprotein E4/E4 3%, apolipoprotein E3/E2 12%, apolipoprotein E3/E4 23% and apolipoprotein E4/E2 2% (6) . apolipoprotein E4 and apolipoprotein E2 differ from apolipoprotein E3 by one of two point mutations resulting in Cys/Arg interchanges (Cys 112 -»· Arg for apolipoprotein E4 and Arg 158 -» Cys for apolipoprotein E2).
Apolipoprotein E also plays a role in immunoregulation and is implicated in the regeneration of the sciatic nerve where it is synthesized by macrophages (7). Apolipoprotein E is a ligand for several receptors: the apolipoprotein (B/E) low density lipoprotein receptor (LDL receptor), the LDL receptor-related protein (LRP), as well as the VLDL receptor, lipolysis-stimulated receptor (LSR) and a newly described apolipoprotein E receptor 2 (3, (8) (9) (10) . The loss of Arg 158 in the apolipoprotein E2 isoform results in a loss of the capacity of apolipoprotein E to bind to the LDL receptor, and subjects developing type III hyperlipoproteinaemia often present the ε2/ε2 phenotype (11, 12) . Apolipoprotein E4 is a risk factor for coronary diseases because of its direct increasing effect on cholesterol levels (13) .
Compelling evidence has recently implicated apolipoprotein E in the development of Alzheimer's disease (14) . There is a dose-response relationship between the ε4 allele and the occurrence of late onset Alzheimer's disease: ε4 homozygosity is a major risk factor for Alzheimer's disease (15) . There is a link between apolipoprotein E4 and early development of the disease and an increased number of senile plaques and fibrillary deposits (16, 17) . In contrast, apolipoprotein E2 would be a longevity factor and seems to play a protective role in Alzheimer's disease (18, 19) .
Because of the implication of particular apolipoprotein E genotypes in cardiovascular or neurodegenerative diseases, we reasoned that the gene product could be involved and we decided to produce large quantities of these proteins for various applications, including the production of a reference material. Such a standard is necessary for developing a reference method suitable in both research and clinical laboratories worldwide.
This report describes the development of an expression system to produce the three apolipoprotein E isoforms in E. coli and the subsequent characterization of the recombinant fusion proteins. Compared to the other apolipoprotein E expression systems previously described in bacteria, ours is able to produce large amounts of recombinant apolipoprotein E that could be easily purified. The first one described in the literature (27) provided some apolipoprotein E that was rapidly proteolyzed, and more recently, another system expressing apolipoprotein E in the periplasm (28) had a very low level of production of the recombinant protein. The major advantage of our expression system is the single-step purification of the recombinant apolipoprotein E. The purification of the recombinant protein expressed in all other expression systems, as the purification of the human plasma apolipoprotein E, requires several Chromatographie steps. The plasma human apolipoprotein E purification needs the isolation of human very low density lipoproteins (VLDL) and several steps of delipidation before the affinity and gel filtration chromatography. In addition our expression system overcomes the extreme difficulties in obtaining more rare phenotypes in the human population such as apolipoprotein E4 and apolipoprotein E2. In contrast to purification after plasmapheresis, our system permits the isolation of purified protein without contamination with other apolipoproteins (apolipoprotein B, apolipoprotein C). E. coli allowed a very rapid inexpensive method for obtaining a high amount of recombinant apolipoprotein E that was purified with a high degree of purity. We have described separately some physicochemical properties of the recombinant apolipoprotein E3 and apolipoprotein E4 (20) .
One of our aims is to compare the different properties of the three isoforms, particularly their conformation, to establish the molecular basis of the difference in reactivity and/or metabolism of the three isoforms, and to understand their involvement in neurodegenerative diseases in order to elucidate the potential protective role of apolipoprotein E2 and the role of apolipoprotein E4 as a risk factor in Alzheimer's disease.
To assess their immunological characteristics, we quantitatively measured the binding of three anti-human apolipoprotein E monoclonal antibodies (21) to plasma apolipoprotein E3 and recombinant apolipoprotein E isoforms (apolipoprotein E2, E3 and E4) by Surface Plasmon Resonance (SPR). Surface Plasmon Resonance detection allows the quantitative real-time measurement of binding interactions between immobilized and solution-phase ligands without radiolabelling or biochemical tagging. The biological activity of the recombinant material was also investigated by testing the LDL-receptor binding activity of apolipoprotein E enriched VLDL preparations in macrophages.
Materials and Methods

Materials
Specific products were from the following suppliers: Taq DNA polymerase from Boehringer Mannheim (Germany), [a- 
Construction of different cDNAs
The cloning of apolipoprotein E3 and apolipoprotein E4 cDNA has been previously described (21) . The apolipoprotein E2 sequence for expression in Escherichia coli was derived by polymerase chain reaction from the mutated sequence of apolipoprotein E2 obtained by direct mutagenesis of the cDNA of apolipoprotein E3 and cloned into the eukaryotic pcDNAIneo vector (Barbier, unpublished). Amplifications were from pcDNAIneo-apolipoprotein E2 using oligonucleotides 5 'GATCCCATGGCTAAGGTGGAGCAAGCGGTGGAG3' as 5' primer and 5'GATCAAGCTTCAGTGATTGTCCCTGGG-CAC3' as 3' primer (underlined sequences correspond to the restriction sites Nco I and Hind III respectively). The reaction contained 15 ng pcDNAIneo-apolipoprotein E2 in 0.075 mol/1 Tris-HCl pH 9.0, 0.020 mol/1 (NH 4 ) 2 SO4, 100 mg/1 Tween 20 buffer supplemented with 0.002 mol/1 MgCl 2 , 0.2 mmol/1 of each dNTP, 0.001 mmol/1 of each primer, 50 ml/1 dimethylsulphoxide, 2 U Taq DNA polymerase. After an initial denaturation step for 6 minutes at 96 °C, amplification was achieved with the following program: l min at 96 °C, 2 min at 60 °C, 3 min at 72 °C, 16 cycles. The PCR product was first cloned in the pCRII vector using the TA cloning kit. The integrity of these new sequences was confirmed by DNA sequencing. The cDNAs were then subcloned in pRSETB expression vectors between Nco I/Hind III restriction sites from which they were recovered by Nde IIHind III restriction digestion and subsequent cloning into the same sites of the modified pARHS2 vectors.
Bacterial expression systems
The pRSETB vector allows the cytoplasmic expression of the complete apolipoprotein E sequence in fusion with a M r 4000 ammoterminal peptide that contains a poly-His stretch. This plasmid is under the control of the strong T7 promoter. pARHS2 expresses the same protein as pRSETB. This very stable plasmid is under the control of the T7 promoter and contains the hok/sok system (hok -host killing, sok -suppression of killing), which leads to cell death for plasmid free cells. For the expression of the apolipoprotein E sequence pRSETB-apolipoprotein E3 and pARHS2-apolipoprotein E3, -apolipoprotein E2 and -apolipoprotein E4 need to be introduced into an E. coli (DE3) strain (F~, ompTri, mg, λ(ΟΕ3)) (22) that carries the T7 RNA polymerase gene under the control of the lacUVS promoter. The BL21 E. coli strain provides an excellent background for expression of recombinant protein since it lacks Ion and ompΤ proteases.
Stability of the expression vectors
To study the stability of the recombinant plasmid, DE3 lysogens that carried the plasmid conferring ampicillin resistance were titered on four plates containing 0.1 g/1 ampicillin, 0.001 mol/1 isopropyl--D-thiogalactopyranoside (IPTG), both or neither. The plasmid stability was followed throughout the production: saturated primary culture, t 0 : time of induction, to + 1 h, t 0 + 3 h, to + 5 h: one hour, three hours and five hours after induction respectively and one growth curve for the E. coli strain was established. One ml of culture was diluted to an Aeoo of 10~5, then 50 μΐ were plated on four different plates containing 0.1 g/1 ampicillin, or 0.001 mol/1 zsopropyl--D-thiogalactopyranoside (IPTG) or both or with neither component. The percentage of cells on the plate/number of viable cells was calculated.
Production and purification E. coli BL21(DE3) strains carrying pRSETB-apolipoprotein E3, pARHS2-apolipoprotein E3, pARHS2-apolipoprotein E2 or pARHS2-apolipoprotein E4 were grown overnight at 37 °C in Luria-Bertani (LB) medium containing 0.1 g/1 ampicillin and then diluted 100-fold into LB-ampicillin medium and grown to a cell density A 600 of 0.6. Then 0.001 mol/1 wopropyl--Z)-thiogalactopyranoside (IPTG) was added and the culture was grown further for 2 to 24 hours. Bacteria from 1 litre of culture were harvested by centrifugation (1000g, 10 min, + 4 °C) and the pellet was resuspended in 40 ml of 0.02 mol/1 Tris-HCl, 0.1 mol/1 NaCl. Lysozyme (15 g/1 in H 2 O) was added to a final concentration of 0.75 g/1 and the sample was incubated at room temperature for 30 minutes. Cells were lysed by sonication (5 bursts, 40 W, 10 s/burst) on ice. RNase and DNase were added to a final concentration of 0.001 g/1 and 0.025 g/1, respectively, and the sample was incubated for 30 min at room temperature. After centrifugation (20000 g, 15 min, + 4 °C) the pellet was resuspended in 40 ml of 0.020 mol/1 TrisHCl, 0.1 mol/1 NaCl containing 1 g/1 Triton X-100 and stirred at room temperature for 30 min. Insoluble material was removed by centrifugation (20000g, 15 min, + 4 °C) and the soluble proteins were precipitated by addition of acetone (final volume fraction 0.6) and recovered by centrifugation (20000g, 15 min, + 4 °C). The pellet was resuspended in 40 ml of 6 mol/1 guanidine-HCl, 0.20 mol/1 sodium phosphate buffer pH 7.8, 0.5 mol/1 NaCl and stirred overnight at + 4 °C. After centrifugation (20000g, 15 min, + 4 °C), the supernatant was filtered through a 0.22 μιη filter and loaded on a Ni-Gel (ProBond gel) column that was previously equilibrated with a 0.20 mol/1 phosphate buffer at pH 7.8 containing 6 mol/1 urea, 0.15 mol/1 NaCl. Two washing steps were performed: first with the equilibration buffer pH 7.8 to remove unbound material, then with the same buffer at pH 6.0. The elution was finally performed with the same buffer at pH 4.O. The fractions were dialyzed extensively against 0.1 mol/1 ammonium bicarbonate, aliquoted and stored at -80 °C. Human apolipoprotein E3 was purified from human plasma very low density lipoproteins of normal ε3/ε3 individuals as previously described (23) .
Characterization of recombinant human apolipoprotein E isoforms by Surface Plasmon Resonance analysis
The analysis was performed on a BIAlite™ apparatus (Pharmacia Biosensor, Sweden) using Surface Plasmon Resonance (24) . Surface Plasmon Resonance uses an optical method to detect changes in the refractive index within a thin dextran matrix. The binding of a soluble protein to an immobilized ligand increases the protein concentration within the matrix. This alters the refractive index within the matrix and this change is quantified in resonance units (R. U.). The response directly correlates with the bound ligand mass. 
Preparation of the sensorchip surface
Kinetic analysis of monoclonal antibody binding to apolipoprotein E
Stock solutions of each of the antibodies were diluted in running buffer (HBS buffer, see "Materials") to a final concentration of 40-1000 nmol/1. For the binding experiments 20 μΐ of antibody were injected at a constant flow rate of 5 μΐ/min (contact time -4 min). The antigen/monoclonal antibody dissociation was followed for 5 min. The sensorchip surfaces were regenerated with 2 mol/1 of formic acid (14 to 20 μΐ, depending on the experiment). Data for the association and the dissociation phases were collected and evaluated to determine the association and dissociation rate constants with the Biaevaluation 2.1 software provided by the manufacturer (25) . All determinations were performed at 25 °C.
A kinetic analysis of the sensorgrams obtained from the interaction of a monoclonal antibody with an immobilized apolipoprotein E was based on the following equation (25):
where R is the plasmon resonance-response unit (R. U.) due to the interaction of the monoclonal antibody with apolipoprotein E in the surface,
A: ass and £ diss are the association (1 · mol" 1 · s" 1 ) and dissociation (s~') rate constants, respectively, C is the molar concentration of injected monoclonal antibody and R max is the R. U. response at saturation of the apolipoprotein E binding sites.
It can be shown that & ass may be determined from the association phase of the sensorgram, i. e., the slope of a plot of monoclonal antibody concentration versus the slopes (called & s ) of dR/dt dependence on R. U. response (25) . A second possibility for determining £ ass is to first calculate A: diss and then to resolve equation (1) , which has now become a first order equation with one unknown value. Values for £ diss can be calculated during the dissociation phase of the sensorgram since as C -»zero, the decay rate (-dR/dt) gives £ diss directly.
LDL-receptor binding
Isolation and enrichment of VLDL
Apolipoprotein E deficient VLDL were isolated by density gradient ultracentrifugation from the serum of apolipoprotein E knockout mice. Purified recombinant or purified human apolipoprotein E were incubated with apolipoprotein E deficient VLDL (0.2 g/g apolipoprotein E deficient VLDL protein) for I hour at 37 °C. The volume was corrected with phosphate buffered saline. Apolipoprotein E enriched VLDL were separated from free apolipoprotein E by another ultracentrifugation step. Control apolipoprotein E deficient VLDL were treated identically. After centrifugation, protein and apolipoprotein E contents were determined and the VLDL were stabilized with 10 g/1 of bovine serum albumin.
Cell and LDL receptor binding studies
J774 Macrophages were grown in 24-well culture plates with Dulbecco's Modified Eagle Medium/fetal calf serum, volume fraction 0.1. Twenty hours before the experiment, the medium was changed to Dulbecco's Modified Eagle Medium/50 ml/1 lipid free human serum. Incubations were performed for 3 hours on melting ice in tetraplot in Dulbecco's Modified Eagle Medium/10 g/1 human serum albumin. [ 125 I]LDL (0.01 g/1) competed with either the respective non-labelled (apolipoprotein E enriched) apolipoprotein E deficient VLDL or with non-labelled LDL (0-0.05 g/1). After incubation, cells were washed 5 times with phosphate buffered saline/ 1 g/1 bovine serum albumin and once with phosphate buffered saline alone. Cells were dissolved in 1 ml of 0.2 mol/1 NaOH. Sevenhundred of the suspension was used for measurement of radioactivity, while 100 was used for cell protein measurements. The binding expressed as a percentage of the control (without competitor) was plotted against the amount of competitor.
Results
Expression vector stability and recombinant apolipoprotein production
To study the stability of the different vectors in the E. coli BL21(DE3) strain and to ascertain whether apolipoprotein production was lethal to the cells, we titered bacteria following zsopropyl-ß-D-thiogalactopyranoside induction on four different media: LB and LB containing ampicillin. wopropyl-ß-D-thiogalactopyranoside, or both. Assuming that recombinant apolipoprotein E is toxic, a) all viable cells would grow on the plate without any additive; b) only cells that retained the plasmid would grow in the presence of ampicillin; c) only cells that had lost plasmid or mutants that had lost the ability to express the apolipoprotein E gene would grow in the presence of z'sopropyl-ß-D-thiogalactopyranoside, d) finally, only mutants that had lost the ability to express the apolipoprotein E gene would grow in the presence of both ampicillin and wopropyl-ß-ZMhiogalactopyranoside.
When cultures of E. coli BL21(DE3)-pRSETB apolipoprotein E were induced by wopropyl-ß-Z)-thiogalactopyranoside, inconsistent and non-reproducible results were observed: a) cell death immediately after induction characterized by total plasmid loss and no production; b) partial loss of the plasmid with slow growth of the remaining cells and low production level; c) no loss of plasmid with slow cell growth and high production level ( fig. 1 ). In addition, the preservation at -80 °C of isolated producing clones resulted in a loss of production capability.
In view of these results the cDNAs of apolipoprotein E were subcloned into the pARHS2 expression vector. This plasmid contains the parB locus, which enhances vector stability.
The stability of the recombinant pARHS2 expression vector was studied throughout the culture. We observed that after induction by zsopropyl-ß-£)-miogalactopyranoside, all viable cells harboured the recombinant vector (results not shown). This vector stability and the concomitant high level production of recombinant protein induced a decrease in the growth rate. After induction with zsopropyl-ß-Z)-thiogalactopyranoside, recombinant E. coli BL21(DE3) cells specifically produced a protein with a M T of 40 000, in accordance with the theoretical relative molecular mass of the recombinant apolipoprotein E. This protein reacted strongly upon immunoblotting with monoclonal anti apolipoprotein E antibodies, thus confirming its authenticity ( fig. 2b ). The production level increased during the first 5 hours of induction (figs. 2a, 2b) reaching about 80 mg/1 (25% of total cell protein) as estimated by scanning of the gels. After 24 hours ( fig. 2a, lane 9 ) the production level was much lower, probably due to cell lysis as no degradation products were visible upon immunoblotting. There were no differences in the production level and the immunological reactivity of the apolipoprotein E expressed in this system. Furthermore all producing clones were stable upon conservation at -80 °C. These results suggested that the production of recombinant human apolipoprotein E is not lethal to the cells when the pARHS2 vector is used.
Recombinant human apolipoproteins E were purified by Ni 2+ -chelating affinity chromatography as previously described (20) . The conditions for the solubilization of the bacterial proteins have changed in order to insure a better yield of purified protein. Determination of the first eight amino acids showed that the sequence corresponded to that predicted from the vector sequence.
Characterization of recombinant apolipoproteins E
Monoclonal antibody-apolipoprotein E interactions studied by Surface Plasmon Resonance
In order to confirm that the immunological properties of the recombinant apolipoproteins E were intact, each protein was tested for binding to several anti-human plasma apolipoprotein E monoclonal antibodies.
To analyze the interaction of monoclonal antibodies 3B7, 1D7 and 3H1 with apolipoprotein E isoforms, apolipoprotein E isoforms (recombinant human apolipoprotein E3, apolipoprotein E2, and apolipoprotein E4 purified from E. coli and human plasma apolipoprotein E3) were immobilized on separate sensorchips by coupling via primary amine groups. The binding of the monoclonal antibodies to apolipoprotein E was measured by Surface Plasmon Resonance and the affinity and kinetic determinations were estimated using the Biaevaluation 2.1 software. As shown in figure 3a, recombinant apolipoproteins E bound with high affinity to the mo- noclonal antibodies, and these interactions were saturable and reversible. Figure 3b shows that the relation between the k s and the monoclonal antibody concentration is linear. These results indicate that the observed signals increase proportionally with the monoclonal antibody concentration thus allowing the estimation of kinetic constants. and without calculation of k s ). The results showed that the three monoclonal antibodies recognized the three recombinant apolipoprotein E isoforms similarly to plasma human apolipoprotein E3 and with close kinetic characteristics.
LDL receptor binding studies
The LDL receptor binding activity of the recombinant apolipoproteins E was assessed using the J774 macrophage cell line. VLDL from apolipoprotein E knockout mice were separately enriched with each of the recombiTab. 1 Kinetic constants of the interaction between three monoclonal anti-apolipoprotein E antibodies and apolipoprotein E isoforms.
Apolipoprotein Antibodies After incubation of the VLDL with the different apolipoprotein E isoforms (human apolipoprotein E3, recombinant apolipoprotein E2, apolipoprotein E3 and apolipoprotein E4), the amount of total proteins and the amount of apolipoprotein E were measured.
nant proteins and with human apolipoprotein E3. The different recombinant apolipoproteins E (recombinant apolipoprotein E2, recombinant apolipoprotein E3 and recombinant apolipoprotein E4) were equally efficient in association with VLDL that does not contain apolipoprotein E. Nevertheless, the ability of the recombinant proteins to associate to apolipoprotein E-deficient VLDL was less efficient than human plasma apolipoprotein E3 (tab. 2). After association, the molar ratio apolipoprotein E : apolipoprotein B48 in VLDL complex was estimated to be 0.6 : 1 for recombinant apolipoprotein E2 and recombinant apolipoprotein E3 and 1 : 1 for recombinant apolipoprotein E4. Each apolipoprotein E-VLDL complex was used in competition with 
Discussion
Expression of human apolipoprotein E was achieved by using plasmid pARHS2, a very stable expression vector containing the parB locus. The parB locus mediates plasmid stabilization by post segregational killing of plasmid free cells (26) . After wopropyl--Z)-thiogalactopyranoside induction 100% of the cells still carried the pARHS2 plasmid containing the apolipoprotein E cDNA. This result indicates a high stability even when expression occurs.
Production was also achieved with the pRSETB plasmid, which showed a high instability in E. coli. The reasons for this instability are not clear because apolipoprotein E was not toxic for cells and we did not observe cell lysis during culture, as described by Vogel et al. (27) . These authors used an expression vector containing the XP L promoter regulated by the thermolabile cl repressor. Their system led to a cellular lysis associated with an intracellular accumulation of apolipoprotein E, followed by a proteolytic destruction of apolipoprotein E 30 min after the induction. This cellular lysis is not a general characteristic of the expression vector, because this vector was used for the production of the human growth hormone and did not show this effect (27) .
Monteilhet et al. (28) described another expression system in E. coli. Expressed sequences were under the control of the T7 promoter and allowed a production level of 15 mg/1 of intact apolipoprotein E. Our system allows the production of 80 mg/1 of apolipoprotein E while the yield of purification was of about 10 mg/1 with a degree of purtiy > 95%, as estimated by SDS-PAGE and gel scanning. This is similar to the level of production obtained with the baculovirus expression system (29), except that our system does not allow post-translational modifications of the protein. Purification of apolipoprotein E routinely requires two chromatography steps (Heparin Sepharose and Sephacryl S300, or DEAE and Heparin Sepharose). Our system allows single step purification of fused proteins whose overall structural characteristics are similar to those of human plasma apolipoprotein E (20) . The Ni 2+ -gel purification procedure is reproducible and faster than others previously described by purifying apolipoproteins E from different sources (27, 28) .
The different experiments of characterization showed that the fusion-peptide did not interfere in the ability of the apolipoprotein E isoforms to bind to antibodies and to LDL receptor. The three monoclonal antibodies bind to the different apolipoprotein E isoforms with high affinity. Recombinant apolipoproteins E are somewhat less immunoreactive with the three antibodies than is purified plasma apolipoprotein E, but the equilibrium dissociation constants (K O ) of the three antibodies with the three recombinant isoforms are similar, and comparable to that of human plasma apolipoprotein E3 (within 2 orders of magnitude). Thus, the presence of the M r 40 000 fusion-peptide did not significantly affect the accessibility of the three epitopes. Our results can be compared to those obtained recently by Raffai' et al. (30) Previously we have shown that the association of recombinant apolipoprotein E3 and E4 with lipids showed the same level of incorporation of the recombinant apolipoprotein E isoforms in di-myristoyl-phosphatidyl-choline particles and, using circular dichroism, the proportion of α helix, β sheets and random coil was similar among the different apolipoproteins E in complexes (20) . Here, we show that our recombinant proteins have the capability to associate with apolipoprotein Edeficient VLDL, nevertheless with a lower efficiency than plasma apolipoprotein E3, and to be active in lipid complexes in binding to the LDL receptor. The LDL receptor binding capability of the recombinant proteins was assessed using the J774 macrophage cell line. When reconstituted with mouse apolipoprotein Edeficient VLDL, recombinant apolipoprotein E3 and recombinant apolipoprotein E4 were as effective as human plasma apolipoprotein E3 in displacing the binding of 125 I-labelled LDL, while recombinant apolipoprotein E2-VLDL complexes were not, as expected from the differential binding of the plasma apolipoprotein E isoforms to the LDL receptor (31) . The lipid association capacity of our recombinant apolipoprotein E is clearly lower than that of human plasma apolipoprotein E3, probably due to the presence of the 42 amino acid fusion peptide. This extension could influence the interaction between N-and C-terminal domains, which composed apolipoprotein E and alter the lipids binding site. Nevertheless, the receptor binding site does not seem impaired.
In summary, the expression system described in this report allows the production of the three human apolipoprotein E isoforms, E2, E3 and E4 as recombinant fusion proteins whose structural and functional characteristics are close to their plasma counterparts. Thus, the pARHS2 vector expressing the apolipoprotein E cDNA in E. coli BL21(DE3) cells is a convenient system for obtaining large quantities of human apolipoprotein E, particularly rare phenotypes.
